The ORR for patients with HER2-positive BC was 31.3% (15/48, 95% CI, 0.200-0.454, Table 2) and the DCR was 83.3% (40/48, 95% CI, 0.704-0.913, Table 2). This evidence concerns the gene ERBB2 and breast cancer.